首页> 外国专利> Algorithmic Approach for Determining the Plasma Genome Abnormality PGA and the Urine genome abnormality UGA scores based on Cell Free cfDNA Copy Number Variations in Plasma and Urine.

Algorithmic Approach for Determining the Plasma Genome Abnormality PGA and the Urine genome abnormality UGA scores based on Cell Free cfDNA Copy Number Variations in Plasma and Urine.

机译:基于血浆和尿液中无细胞cfDNA拷贝数变异的血浆基因组异常PGA和尿液基因组异常UGA评分的算法方法。

摘要

The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
机译:本发明涉及使用无细胞DNA分析指导晚期前列腺癌治疗的方法。特别地,从患者的尿液和/或血浆中收集液体活检样品,以测量与转移性前列腺癌相关的无细胞DNA的拷贝数变化。尤其是,尿液基因组异常(UGA)和血浆基因组异常(PGA)值可用于预测晚期前列腺癌患者的治疗反应,以及用于在激素敏感阶段做出与雄激素剥夺疗法(ADT)治疗结果相关的决策并在去势抵抗性晚期癌症阶段开始或改变化疗方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号